Inhibikase Therapeutics, Inc. (IKT) Current Ratio
- Current ratio · latest quarter: Value 15.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 15.82× | Current assets / current liabilities. $162.34M ÷ $10.26M ≈ 15.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 162.34M USD | Assets, Current |
| Current obligations | 10.26M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 127.81M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 991.72K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $162.34M | $10.26M | (m) | $127.81M | (m) | (m) | $991.72K | (m) | 15.82× |
| 2026-03-31 | $172.18M | $5.71M | (m) | $120.80M | (m) | (m) | $1.59M | (m) | 30.14× |
| 2025-12-31 | $180.11M | $8.30M | (m) | $39.54M | (m) | (m) | $1.16M | (m) | 21.70× |
| 2025-09-30 | $78.54M | $6.70M | (m) | $39.05M | (m) | (m) | $620.53K | (m) | 11.73× |
| 2025-06-30 | $88.79M | $8.80M | (m) | $9.92M | (m) | (m) | $2.70M | (m) | 10.09× |
| 2025-03-31 | $94.16M | $8.55M | (m) | $19.74M | (m) | (m) | $1.69M | (m) | 11.01× |
| 2024-12-31 | $98.45M | $3.73M | $97.50M | $41.05M | (m) | (m) | $943.02K | (m) | 26.37× |
| 2024-09-30 | $4.19M | $4.91M | (m) | $2.33M | (m) | (m) | $2.53M | (m) | 0.85× |
| 2024-06-30 | $8.60M | $3.70M | (m) | $4.85M | (m) | (m) | $1.34M | (m) | 2.32× |
| 2024-03-31 | $10.81M | $4.23M | (m) | $7.40M | (m) | (m) | $1.29M | (m) | 2.55× |
| 2023-12-31 | $14.21M | $3.44M | $9.20M | $4.09M | (m) | (m) | $646.77K | (m) | 4.13× |
| 2023-09-30 | $17.55M | $2.74M | (m) | $1.97M | (m) | (m) | $734.56K | (m) | 6.40× |
| 2023-06-30 | $21.98M | $2.73M | (m) | $19.03M | (m) | (m) | $754.15K | (m) | 8.04× |
| 2023-03-31 | $27.63M | $2.66M | (m) | $21.76M | (m) | (m) | $959.08K | (m) | 10.37× |
| 2022-12-31 | $24.37M | $3.70M | $7.19M | $15.86M | (m) | (m) | $1.15M | (m) | 6.59× |
| 2022-09-30 | $27.99M | $3.21M | (m) | $20.75M | (m) | (m) | $781.22K | (m) | 8.71× |
| 2021-12-31 | $42.47M | $4.05M | $40.75M | $0.00 | (m) | (m) | $1.09M | (m) | 10.47× |
| 2021-03-31 | $11.87M | $3.59M | (m) | (m) | (m) | (m) | $715.02K | (m) | 3.31× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |